Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comtifator - Bristol Myers Squibb

Next Previous
Drug Profile

Comtifator - Bristol Myers Squibb

Alternative Names: BMS 986419; eIF2b activator - Bristol-Myers Squibb; EOAI-4018683; EVT-8683

Latest Information Update: 26 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evotec SE
  • Developer Bristol-Myers Squibb; Evotec SE
  • Class Acetamides; Antidementias; Chlorobenzenes; Ethers; Fluorobenzenes; Fluorocarbons; Oxadiazoles; Piperidines; Small molecules
  • Mechanism of Action Eukaryotic initiation factor 2b stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurodegenerative disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 26 Aug 2026 Phase I development is still ongoing for Neurodegenerative disorders (In volunteers) in USA (Evotec SE pipeline, August 2026)
  • 14 Aug 2026 Discontinued - Phase-I for Alzheimer's disease (unspecified route) (Bristol-Myers Squibb pipeline, August 2026)
  • 28 Jun 2026 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top